Please login to the form below

Not currently logged in
Email:
Password:

testosterone

This page shows the latest testosterone news and features for those working in and with pharma, biotech and healthcare.

FDA approves Myovant’s oral pill Orgovyx for prostate cancer

FDA approves Myovant’s oral pill Orgovyx for prostate cancer

In this study, Orgovyx achieved sustained testosterone suppression to castrate levels in 96.7% of patients from week five to week 48, in comparison to 88.8% for those receiving leuprolide ... It is designed to block the GnRH receptor, which in return

Latest news

More from news
Approximately 1 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • Reaching patients and HCPs during the pandemic Reaching patients and HCPs during the pandemic

    Clarus Therapeutics pushed through with the launch of its testosterone replacement tablet, Jatenzo, despite the disruption caused by COVID-19.

  • Case study: Tackle TD for Bayer UK Case study: Tackle TD for Bayer UK

    Client:Bayer UK. Agency:Virgo Health and Oi Ltd. Campaign:Tackle TD. Timescale:N/A. Testosterone deficiency affects around one million British men, but symptoms like fatigue are often ignored, and ... One million British men are estimated to have

  • Deal Watch April 2016 Deal Watch April 2016

    50 . Acerus (CA). Aytu (US). US license and commercialisation. Approved nasal testosterone for treatment of hypogonadism.

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    130. TesoRx Pharma/Aspen. Licence [C]. For TSX 002 an unmodified oral  testosterone replacement.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....